Evidence map›Paper›PMID 33154371›Full record

ArticleNature communications2020

ATF4 leads to glaucoma by promoting protein synthesis and ER client protein load.

Ramesh B Kasetti, Pinkal D Patel, Prabhavathi Maddineni, Shruti Patil, Charles Kiehlbauch, J Cameron Millar, Charles C Searby, VijayKrishna Raghunathan, Val C Sheffield, Gulab S Zode

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Targeting the Glutaminolysis Pathway in Glaucoma-Associated Fibrosis.International journal of molecular sciences · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. A lead role for a "secondary" axonal injury response.Neural regeneration research · 2025
    Article
  19. Article
  20. Protein misfolding and mitochondrial dysfunction in glaucoma.Frontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ramesh B KasettiDepartment of Pharmacology and Neuroscience and the North Texas Eye Research Institute, University of North Texas Health Science Center at Fort Worth, TX, 76107, Fort Worth, USA.
Pinkal D PatelDepartment of Pharmacology and Neuroscience and the North Texas Eye Research Institute, University of North Texas Health Science Center at Fort Worth, TX, 76107, Fort Worth, USA.
Prabhavathi MaddineniDepartment of Pharmacology and Neuroscience and the North Texas Eye Research Institute, University of North Texas Health Science Center at Fort Worth, TX, 76107, Fort Worth, USA.
Shruti PatilDepartment of Pharmacology and Neuroscience and the North Texas Eye Research Institute, University of North Texas Health Science Center at Fort Worth, TX, 76107, Fort Worth, USA.ORCID 0000-0002-8173-0165
Charles KiehlbauchDepartment of Pharmacology and Neuroscience and the North Texas Eye Research Institute, University of North Texas Health Science Center at Fort Worth, TX, 76107, Fort Worth, USA.
J Cameron MillarDepartment of Pharmacology and Neuroscience and the North Texas Eye Research Institute, University of North Texas Health Science Center at Fort Worth, TX, 76107, Fort Worth, USA.
Charles C SearbyDepartment of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA, 52242, USA.
VijayKrishna RaghunathanDepartment of Basic Sciences and the Ocular Surface Institute, College of Optometry, University of Houston, Houston, TX, USA.ORCID 0000-0003-1702-591X
Val C SheffieldDepartment of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA, 52242, USA.ORCID 0000-0002-6282-0835
Gulab S ZodeDepartment of Pharmacology and Neuroscience and the North Texas Eye Research Institute, University of North Texas Health Science Center at Fort Worth, TX, 76107, Fort Worth, USA. gulab.zode@unthsc.edu.
University of North Texas · USUniversity of Iowa · USUniversity of Houston · US

Funding

Stem Cell and Organoid CoreP30EY025580 · NEI · UNIVERSITY OF IOWA · PI Budd A Tucker · 2016 to 2026
$6.9M
Crosstalk Between Unfolded Protein Response and Autophagy for the Treatment of GlaucomaR01EY026177 · NEI · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI ZODE, GULAB · 2016 to 2025
$3.8M
Novel Genome Editing for the Treatment of GlaucomaR01EY030366 · NEI · UNIVERSITY OF IOWA · PI CLARK, ABBOT FREDERICK, SHEFFIELD, VAL C. · 2019 to 2023
$2.7M
Targeting ER Stress Pathway Using Sodium 4-Phenylbutyrate for the Treatment of POAGR01EY028616 · NEI · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI ZODE, GULAB · 2018 to 2021
$1.4M
NEI NIH HHS P30 EY025580NEI NIH HHS R01 EY026177NEI NIH HHS R01 EY028616NEI NIH HHS R01 EY030366
6 · The paper itself

Abstract

The underlying pathological mechanisms of glaucomatous trabecular meshwork (TM) damage and elevation of intraocular pressure (IOP) are poorly understood. Here, we report that the chronic endoplasmic reticulum (ER) stress-induced ATF4-CHOP-GADD34 pathway is activated in TM of human and mouse glaucoma. Expression of ATF4 in TM promotes aberrant protein synthesis and ER client protein load, leading to TM dysfunction and cell death. These events lead to IOP elevation and glaucomatous neurodegeneration. ATF4 interacts with CHOP and this interaction is essential for IOP elevation. Notably, genetic depletion or pharmacological inhibition of ATF4-CHOP-GADD34 pathway prevents TM cell death and rescues mouse models of glaucoma by reducing protein synthesis and ER client protein load in TM cells. Importantly, glaucomatous TM cells exhibit significantly increased protein synthesis along with induction of ATF4-CHOP-GADD34 pathway. These studies indicate a pathological role of ATF4-CHOP-GADD34 pathway in glaucoma and provide a possible treatment for glaucoma by targeting this pathway.

Indexed as

Endoplasmic Reticulum StressProtein BiosynthesisActivating Transcription Factor 4AnimalsAqueous HumorCell DeathCells, CulturedGlaucoma, Open-AngleHumansMiceOcular HypertensionOptic NerveProtein Phosphatase 1Retinal Ganglion CellsSignal TransductionTrabecular MeshworkActivating Transcription Factor 4Protein Phosphatase 1Transcription Factor CHOP

Identifiers

PMID33154371
PMCPMC7644693
OpenAlexW3094703137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.